Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial.

Eric Renard¹, Ruth S Weinstock², Alfred Penfornis³, Jean-Pierre Riveline⁴, Charles Thivolet⁵, Trang T Ly⁶,

¹Department of Endocrinology and Diabetes, Montpellier University Hospital; INSERM CIC1411 Clinical Investigation Center, Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, Montpellier, France.

²Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.

³Hospital Center Sud Francilien, Paris-Saclay University, Corbeil-Essonnes, France.

⁴Lariboisière Hospital, Paris Cité University, Paris, France.

⁵DIAB-eCARE Diabetes Center, Lyon, France.

⁶Insulet Corporation, Acton, Massachusetts, USA.

PubMed DOI

Abstract

BACKGROUND: The Omnipod 5 Automated Insulin Delivery (AID) System is safe and effective for individuals managing Type 1 diabetes (T1D). Longer-term studies may provide additional evidence of sustained effectiveness and safety of AID system use in T1D. METHODS: This 12-month extension study was conducted following a multicenter randomized controlled trial (RCT) where participants used either AID (…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.